Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
You may also be interested in...
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
Legal Briefs: Courts On Exclusivity; Namenda ‘Hard Switch’ Deemed Coercive; Acorda Fights Bass Patent Petition
FDA’s active moiety rationale for denying Vascepa five years exclusivity is rejected by district court; Actavis strategy to protect Namenda franchise meets another hurdle; Acorda challenges ‘improper purpose’ of Bass IPR petition.